#ESMO20: Amgen team nails down solid early evidence of AMG 510’s potential for NSCLC, unlocking the door to a wave of KRAS programs

The first time I sat down with Amgen’s Greg Friberg to talk about the pharma giant’s KRAS G12C program for sotorasib (AMG 510) at ASCO a little more than a year ago, there was high excitement about the first glimpse of efficacy from their Phase I study, with 5 of…

Click to view original post